No products in the cart.
Pre-made Ficlatuzumab benchmark antibody ( Whole mAb, anti-HGF therapeutic antibody, Anti-DFNB39/F-TCF/HPTA/SF Antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-212
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Ficlatuzumab biosimilar, Whole mAb, Anti-HGF Antibody: Anti-DFNB39/F-TCF/HPTA/SF therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Ficlatuzumab is a humanized monoclonal antibody designed for the treatment of cancers.
| Products Name (INN Index) | Pre-Made Ficlatuzumab biosimilar, Whole mAb, Anti-HGF Antibody: Anti-DFNB39/F-TCF/HPTA/SF therapeutic antibody |
|---|---|
| INN Name | Ficlatuzumab |
| Target | HGF |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2011 |
| Year Recommended | 2012 |
| Companies | AVEO Oncology,AVEO Pharmaceuticals,Dana-Farber Cancer Institute,University of Arizona Cancer Center,University of California at San Francisco |
| Conditions Approved | NA |
| Conditions Active | Head and neck cancer,Non-small cell lung cancer,Acute myeloid leukaemia,Pancreatic cancer |
| Conditions Discontinued | Lymphoma,Multiple myeloma,Solid tumours,Glioblastoma |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | HGF |
| Package |
Previous slide
Next slide
